ADDEX THERAP.ADR NEW/120

ADDEX THERAP.ADR NEW/120

Depository Receipt · US00654J2069 · ADXN · A3EXC6 (XNCM)
Overview
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of ADDEX THERAP.ADR NEW/120
No Price
29.04.2026 08:26
Current Prices from ADDEX THERAP.ADR NEW/120
ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
ADXN
USD
29.04.2026 08:26
6,90 USD
0,16 USD
+2,37 %
XDQU: Quotrix
Quotrix
ATSANA69.DUSD
EUR
29.04.2026 05:27
5,80 EUR
0,00 EUR
XDUS: Düsseldorf
Düsseldorf
ATSANA69.DUSB
EUR
28.04.2026 17:31
5,40 EUR
-0,40 EUR
-6,90 %
IEXG: IEX
IEX
ADXN
USD
28.04.2026 15:38
6,50 USD
-0,09 USD
-1,37 %
Company Profile for ADDEX THERAP.ADR NEW/120 Depository Receipt
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot–Marie–Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.

Company Data

Name ADDEX THERAP.ADR NEW/120
Company Addex Therapeutics Ltd
Symbol ADXN
Website https://www.addextherapeutics.com
Primary Exchange XNCM Frankfurt
WKN A3EXC6
ISIN US00654J2069
Asset Class Depository Receipt
Sector Healthcare
Industry Biotechnology
CEO Timothy Mark Dyer
Country Switzerland
Currency EUR
Employees 0,0 T
Address Chemin des Mines, 9, 1202 Geneva
IPO Date 2020-02-12

Stock Splits

Date Split
23.10.2023 1:20

Ticker Symbols

Name Symbol
Düsseldorf ATSANA69.DUSB
Frankfurt APE1.F
NASDAQ ADXN
Quotrix ATSANA69.DUSD
More Shares
Investors who hold ADDEX THERAP.ADR NEW/120 also have the following shares in their portfolio:
INVESTEC BANK PLC PHOENIX KO NTS CAR 08/11/23
INVESTEC BANK PLC PHOENIX KO NTS CAR 08/11/23 Bond
Labo Print S.A.
Labo Print S.A. Share